> top > docs > PubMed:25627160 > annotations

PubMed:25627160 JSONTXT

Annnotations TAB JSON ListView MergeView

PubMed_Structured_Abstracts

Id Subject Object Predicate Lexical cue
T1 110-592 BACKGROUND denotes The molecular mechanisms underlying autistic behaviors remain to be elucidated. Mutations in genes linked to autism adversely affect molecules regulating dendritic spine formation, function and plasticity, and some increase the mammalian target of rapamycin, mTOR, a regulator of protein synthesis at spines. Here, we investigated whether the Akt/mTOR pathway is disrupted in idiopathic autism and in rats exposed to valproic acid, an animal model exhibiting autistic-like behavior.
T2 602-1006 METHODS denotes Components of the mTOR pathway were assayed by Western blotting in postmortem fusiform gyrus samples from 11 subjects with idiopathic autism and 13 controls and in valproic acid versus saline-exposed rat neocortex. Additionally, protein levels of brain-derived neurotrophic factor receptor (TrkB) isoforms and the postsynaptic organizing molecule PSD-95 were measured in autistic versus control subjects.
T3 1016-1380 RESULTS denotes Full-length TrkB, PI3K, Akt, phosphorylated and total mTOR, p70S6 kinase, eIF4B and PSD-95 were reduced in autistic versus control fusiform gyrus. Similarly, phosphorylated and total Akt, mTOR and 4E-BP1 and phosphorylated S6 protein were decreased in valproic acid- versus saline-exposed rats. However, no changes in 4E-BP1 or eIF4E were found in autistic brains.
T4 1394-1900 CONCLUSIONS denotes In contrast to some monogenic disorders with high rates of autism, our data demonstrate down-regulation of the Akt/mTOR pathway, specifically via p70S6K/eIF4B, in idiopathic autism. These findings suggest that disruption of this pathway in either direction is widespread in autism and can have adverse consequences for synaptic function. The use of valproic acid, a histone deacetylase inhibitor, in rats successfully modeled these changes, implicating an epigenetic mechanism in these pathway disruptions.

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 146-164 HP_0000729 denotes autistic behaviors
T2 146-154 HP_0000717 denotes autistic
T3 219-225 HP_0000717 denotes autism
T4 497-503 HP_0000717 denotes autism
T5 569-577 HP_0000717 denotes autistic

NEUROSES

Id Subject Object Predicate Lexical cue
T1 0-9 PATO_0001997 denotes Decreased
T2 1112-1119 PATO_0001997 denotes reduced
T3 1255-1264 PATO_0001997 denotes decreased
T4 72-79 PATO_0001646 denotes exposed
T5 516-523 PATO_0001646 denotes exposed
T6 794-801 PATO_0001646 denotes exposed
T7 1297-1304 PATO_0001646 denotes exposed
T8 72-79 PATO_0002425 denotes exposed
T9 516-523 PATO_0002425 denotes exposed
T10 794-801 PATO_0002425 denotes exposed
T11 1297-1304 PATO_0002425 denotes exposed
T17 243-252 CHEBI_25367 denotes molecules
T18 940-948 CHEBI_25367 denotes molecule
T19 264-273 PATO_0002045 denotes dendritic
T20 291-299 PATO_0000173 denotes function
T21 1722-1730 PATO_0000173 denotes function
T22 358-367 CHEBI_9168 denotes rapamycin
T23 390-397 CHEBI_16541 denotes protein
T24 831-838 CHEBI_16541 denotes protein
T25 1242-1249 CHEBI_16541 denotes protein
T26 390-397 CHEBI_36080 denotes protein
T27 831-838 CHEBI_36080 denotes protein
T28 1242-1249 CHEBI_36080 denotes protein
T29 473-482 PATO_0001507 denotes disrupted
T30 680-688 PATO_0002400 denotes fusiform
T31 1147-1155 PATO_0002400 denotes fusiform
T32 1021-1027 PATO_0000122 denotes length
T33 1045-1059 PATO_0002220 denotes phosphorylated
T34 1174-1188 PATO_0002220 denotes phosphorylated
T35 1224-1238 PATO_0002220 denotes phosphorylated
T36 1439-1443 PATO_0000469 denotes high
T37 1487-1497 PATO_0000076 denotes regulation
T38 1641-1650 PATO_0000039 denotes direction

BLAH2015_Annotations_test_5

Id Subject Object Predicate Lexical cue
T1 72-79 PATO_0002425 denotes exposed
T5 83-96 CHEBI_39867 denotes valproic acid
T10 243-252 CHEBI_25367 denotes molecules
T12 264-273 PATO_0002045 denotes dendritic
T13 291-299 PATO_0000173 denotes function
T15 358-367 CHEBI_9168 denotes rapamycin
T16 390-397 CHEBI_36080 denotes protein
T35 390-397 PM7566 denotes protein
T19 390-397 CHEBI_16541 denotes protein
T22 473-482 PATO_0001507 denotes disrupted
T2 516-523 PATO_0002425 denotes exposed
T6 527-540 CHEBI_39867 denotes valproic acid
T23 680-688 PATO_0002400 denotes fusiform
T33 680-694 PM4231 denotes fusiform gyrus
T38 711-719 Patient denotes subjects
T7 766-779 CHEBI_39867 denotes valproic acid
T3 794-801 PATO_0002425 denotes exposed
T17 831-838 CHEBI_36080 denotes protein
T36 831-838 PM7566 denotes protein
T20 831-838 CHEBI_16541 denotes protein
T11 940-948 CHEBI_25367 denotes molecule
T25 1021-1027 PATO_0000122 denotes length
T26 1045-1059 PATO_0002220 denotes phosphorylated
T34 1147-1161 PM4231 denotes fusiform gyrus
T24 1147-1155 PATO_0002400 denotes fusiform
T27 1174-1188 PATO_0002220 denotes phosphorylated
T28 1224-1238 PATO_0002220 denotes phosphorylated
T21 1242-1249 CHEBI_16541 denotes protein
T37 1242-1249 PM7566 denotes protein
T18 1242-1249 CHEBI_36080 denotes protein
T8 1268-1281 CHEBI_39867 denotes valproic acid
T4 1297-1304 PATO_0002425 denotes exposed
T29 1439-1443 PATO_0000469 denotes high
T30 1487-1497 PATO_0000076 denotes regulation
T31 1641-1650 PATO_0000039 denotes direction
T14 1722-1730 PATO_0000173 denotes function
T9 1743-1756 CHEBI_39867 denotes valproic acid
T32 1760-1789 CHEBI_61115 denotes histone deacetylase inhibitor
T39 997-1005 Patient denotes subjects